Rabia Gurses Ozden - 03 Feb 2024 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Feb 2024, 18:32:10 UTC
Prior SEC filing
02 Feb 2024
Next SEC filing
20 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Donald Notman, Attorney-in-Fact for Rabia Gurses Ozden
Filing notes and source

Key filing fact

Rabia Gurses Ozden filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 06 Feb 2024.

Key facts

  • This page summarizes Rabia Gurses Ozden's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 06 Feb 2024, 18:32.

Change

  • Previous filing in this sequence was filed on 02 Feb 2024.
  • Current net transaction value: +$30,842.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Award

Transaction value
$0
Shares
+66,633
Change %
+72%
Price
$0.000000
Shares after
159,400
Date
03 Feb 2024
Ownership
Direct
Footnotes
F1
OCUL transaction

Common Stock

Sale

Transaction value
$30,842
Shares
+6,346
Change %
+4.3%
Price
$4.86
Shares after
153,054
Date
05 Feb 2024
Ownership
Direct
Footnotes
F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+200,000
Change %
Price
$0.000000
Shares after
200,000
Date
03 Feb 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
200,000
Exercise price
$5.18
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On February 3, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

Footnote F2

Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2024. The sales do not represent a discretionary trade by the reporting person.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.94, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

Footnote F4

Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .